An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma.
Nishihori T et al. Eur J Haematol. 2015 Jan 20. doi: 10.1111/ejh.12509. [Epub ahead of print].

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myelomanot eligible for or who deferred autologous stem cell transplantation.
Girnius SK et al. Br J Haematol. 2015 Jan 8. doi: 10.1111/bjh.13243. [Epub ahead of print].

Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution.
Rosiñol L et al. Bone Marrow Transplant. 2015 Jan 26. doi: 10.1038/bmt.2014.320. [Epub ahead of print].

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.
Iacobelli S et al. Bone Marrow Transplant. 2015 Jan 26. doi: 10.1038/bmt.2014.310. [Epub ahead of print].

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: Subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Moreau P et al. Haematologica. 2015 Jan 16. pii: haematol.2014.118182. [Epub ahead of print].